Master Nitrosoureas with Picmonic for Medicine

Nitrosoureas require bioactivation by liver. This process involves hepatic cytochrome P450 enzymes.

Alkylating agents are a class of antineoplastic drugs that transfer alkyl groups to DNA. This may result in the inhibition of protein synthesis that usually promotes cell growth. Alkylating agents are cell-cycle nonspecific.

When DNA is alkylated, alkyl group can form bonds between their hydrogen atoms. This cross-linking can occur between opposite strands, called interstrand, or within the same strand, called intrastrand. Cancer cells are most susceptible because of their high cell division rates.

Nitrosoureas are lipophilic, which can cross the blood-brain barrier. Because of this ability, nitrosoureas are useful for treating CNS neoplasms.

These drugs are indicated for primary gliomas such as glioblastoma and other CNS neoplasms (e.g. brainstem glioma, medulloblastoma, ependymoma, and astrocytoma). Although they have been traditionally used for multiple myeloma and lymphomas, they are not commonly used now for these indications given their signifcant toxicity in comparison to other chemotherapeutic regimens.

Because nitrosoureas affect all cells, normal cells characterized by rapid dividing cells such as hematopoietic, endothelial, and reproductive cells can be impacted. Bone marrow is the most sensitive tissue, resulting in bone marrow suppression (myelosuppression).

Pulmonary toxicity can occur and progress to irreversible pulmonary fibrosis. This adverse effect is dose-dependent. Patients may present with cough, dyspnea, reduced diffusion capacity, and a restrictive pulmonary function test pattern.

Signs and symptoms of central nervous system (CNS) toxicity include seizure, dizziness, and ataxia. Reversible hepatotoxicity is also seen in a small percentage of patients taking these medications.

Carmustine is also known as BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea). It forms intrastrand cross-links by binding to the N7 position of guanine. Carmustine can be given via intravenous injection to treat cerebal neoplasms, hodgkin and non-Hodgkin lymphomas, and multiple myeloma. Uniquely, carmustine can be used as an intracerebral implant (Gliadel wafer®) as adjunctive treatment of newly-diagnosed high-grade glioma or recurrent glioblastoma. Nausea and vomiting can develop 2 hours after administration and last in 4-6 hours.

Lomustine is also known as CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea). Lomustine is only administered orally, and it can be used for throat and larynx tumors, central nervous system tumors, lymphogranulomatosis, lung, and gastrointestinal tract cancer. Nausea and vomiting can develop 3-6 hours after administration.